246 related articles for article (PubMed ID: 18669437)
1. Pharmaceutical promotion and First Amendment rights.
Troy DE; Gottlieb S
N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
[No Abstract] [Full Text] [Related]
2. Pharmaceutical promotion to physicians and First Amendment rights.
Kesselheim AS; Avorn J
N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
[No Abstract] [Full Text] [Related]
3. Off-label marketing and the First Amendment.
Boumil MM
N Engl J Med; 2013 Jan; 368(2):103-5. PubMed ID: 23234470
[No Abstract] [Full Text] [Related]
4. Higher First Amendment hurdles for public health regulation.
Outterson K
N Engl J Med; 2011 Aug; 365(7):e13. PubMed ID: 21812665
[No Abstract] [Full Text] [Related]
5. Prescriptions, privacy, and the First Amendment.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2011 May; 364(21):2053-5. PubMed ID: 21524208
[No Abstract] [Full Text] [Related]
6. Shifting terrain in the regulation of off-label promotion of pharmaceuticals.
Mello MM; Studdert DM; Brennan TA
N Engl J Med; 2009 Apr; 360(15):1557-66. PubMed ID: 19357413
[No Abstract] [Full Text] [Related]
7. Inconsistent government policies: why FDA off-label regulation cannot survive First Amendment review under Greater New Orleans.
Hall RF; Sobotka E
Food Drug Law J; 2007; 62(1):1-48. PubMed ID: 17444025
[No Abstract] [Full Text] [Related]
8. Good law from tragic facts--Congress, the FDA, and preemption.
Annas GJ
N Engl J Med; 2009 Sep; 361(12):1206-11. PubMed ID: 19759383
[No Abstract] [Full Text] [Related]
9. Clinical trial transparency--antidote to weaker off-label-promotion rules?
Outterson K
N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
[No Abstract] [Full Text] [Related]
10. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
11. Off-label or off-limits?
Ratner M; Gura T
Nat Biotechnol; 2008 Aug; 26(8):867-75. PubMed ID: 18688236
[No Abstract] [Full Text] [Related]
12. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.
Vladeck DC
Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967
[No Abstract] [Full Text] [Related]
13. A strike against preemption.
Nat Biotechnol; 2009 May; 27(5):397. PubMed ID: 19430422
[TBL] [Abstract][Full Text] [Related]
14. The Supreme Court, preemption, and malpractice liability.
Kesselheim AS; Studdert DM
N Engl J Med; 2009 Feb; 360(6):559-61. PubMed ID: 19196672
[No Abstract] [Full Text] [Related]
15. Forbidden and Permitted Statements about Medications--Loosening the Rules.
Avorn J; Sarpatwari A; Kesselheim AS
N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
[No Abstract] [Full Text] [Related]
16. Direct-to-consumer genetic tests, government oversight, and the First Amendment: what the government can (and can't) do to protect the public's health.
Javitt GH; Stanley E; Hudson K
Oklahoma Law Rev; 2004; 57(2):251-302. PubMed ID: 15658034
[No Abstract] [Full Text] [Related]
17. Smoking and the First Amendment.
Outterson K
N Engl J Med; 2011 Dec; 365(25):2351-3. PubMed ID: 22149735
[No Abstract] [Full Text] [Related]
18. Impossible? Outlawing state safety laws for generic drugs.
Glantz LH; Annas GJ
N Engl J Med; 2011 Aug; 365(8):681-3. PubMed ID: 21830958
[No Abstract] [Full Text] [Related]
19. Health related claims, the market for information, and the first amendment.
Beales JH
Health Matrix Clevel; 2011; 21(1):7-30. PubMed ID: 21847896
[No Abstract] [Full Text] [Related]
20. Free speech rights outweigh restrictions on promoting drugs off label, court rules.
Roehr B
BMJ; 2012 Dec; 345():e8324. PubMed ID: 23220261
[No Abstract] [Full Text] [Related]
[Next] [New Search]